The goal of this article is to discuss best practises in regenerative medicine. In orthopaedic disorders, we use autologous expanded mesenchymal stem cells (MSCs) paired with platelet-rich plasma (PRP) as an alternative to surgical intervention for cartilage and tendon restoration. All major traumatic damage to synovial joints result in osteoarthritis (OA), which is an absolute and common course. OA is the most common type of degenerative joint disease, and it is a leading cause of pain and disability. Despite the global growth of OA, no viable pharmacotherapies exist to repair the unique structure and function of damaged articular cartilage. Tendon tears never heal on their own due to a lack of blood flow, and surgical repair is currently the only option for symptomatic tears. As a result, cell-based and biological treatments for OA and related orthopaedic disorders are becoming more popular research and development topics. For the past two decades, autologous MSCs have been used to treat osteoarthritis and other orthopaedic diseases, although it is still considered experimental therapy.
Author(S) Details
Hassan Mubark
Department of Rheumatology, Auckland Regenerative Clinic, Ormiston Specialist Centre, New Zealand.
View Book:- https://stm.bookpi.org/IDMMR-V3/article/view/5470
No comments:
Post a Comment